Nabriva Therapeutics AG

General Information

We are a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. We are developing our lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous, or IV, and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia, or CABP and intend to develop lefamulin for additional indications other than pneumonia. We have completed a Phase 2 clinical trial of lefamulin for acute bacterial skin and skin structure infections, or ABSSSI. Based on the clinical results of lefamulin for ABSSSI, as well as its rapid tissue distribution, including substantial penetration into lung tissue and fluids, we are preparing to initiate two pivotal, international Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP.

Employees: 42
Founded: 2005
Contact Information
Address Leberstrasse 20, 1110 Vienna, Austria
Phone Number +43 (0)1 740 930
Web Address
View Prospectus: Nabriva Therapeutics AG
Financial Information
Market Cap $94.5mil
Revenues $2.5 mil (last 12 months)
Net Income $-26.8 mil (last 12 months)
IPO Profile
Symbol NBRV
Exchange NASDAQ
Shares (millions): 9.0
Price range $10.25 - $10.25
Est. $ Volume $92.3 mil
Manager / Joint Managers Leerink Partners/ RBC Capital Markets
CO-Managers Needham & Company/ Wedbush PacGrow
Expected To Trade: 9/18/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change